LYRFIGTU (ELEVAR THERAPEUTICS INC): FDA ORIG Approval, Not disclosed in the FDA record.

Key facts

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What was approved

FDA's record shows ELEVAR THERAPEUTICS INC as the sponsor of LYRFIGTU, with the generic name recorded as unspecified and dosage form CAPSULE. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. This specific application is submission type ORIG (submission number 1) under application number NDA220425, with a submission status date of 20260923. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

ELEVAR THERAPEUTICS INC’s FDA history

Argus HQ has recorded 1 total FDA action tied to ELEVAR THERAPEUTICS INC: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

Frequently asked questions

What did FDA approve?

FDA's record shows nda approval for LYRFIGTU (unspecified), dosage form CAPSULE, sponsored by ELEVAR THERAPEUTICS INC, under application number NDA220425. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What does the submission type mean?

A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information.

Is this product available now?

FDA's record lists a submission status date of 20260923. Availability, pricing, and distribution details beyond the submission status date are Not disclosed in the FDA record. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Does ELEVAR THERAPEUTICS INC have other FDA approval records?

This is the only FDA action Argus HQ has on file for ELEVAR THERAPEUTICS INC so far. Argus ingests new FDA records daily.

Related enforcement actions

• Approval (recent): SHANDONG — ANDA approval: SUGAMMADEX SODIUM (unspecified) →
• Approval (recent): PIRAMAL CRITICAL — ANDA approval: DESFLURANE (unspecified) →
• Approval (recent): AUROBINDO PHARMA LTD — ANDA approval: PERAMPANEL (unspecified) →
• Approval (recent): TARO — ANDA approval: LOPERAMIDE HYDROCHLORIDE (unspecified) →
• Approval (recent): LUPIN — ANDA approval: PHYTONADIONE (unspecified) →
• Approval (recent): EVER VALINJECT — NDA approval: Unspecified (unspecified) →
• Approval (recent): GLAND — ANDA approval: LEVOCARNITINE (unspecified) →
• Approval (recent): ABBVIE INC — NDA approval: JUVMO (unspecified) →